NBI-1117568
Sponsors
Neurocrine Biosciences Inc., Neurocrine Biosciences
Conditions
Bipolar I DisorderManiaSchizophrenia
Phase 2
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
CompletedNCT05545111
Start: 2022-10-04End: 2024-07-10Updated: 2025-07-11
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
RecruitingNCT07288320
Start: 2025-12-24End: 2028-02-01Target: 150Updated: 2026-07-31
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RecruitingNCT06963034
Start: 2025-05-08End: 2027-10-01Target: 284Updated: 2026-03-06
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RecruitingNCT07105098
Start: 2025-08-11End: 2027-11-01Target: 284Updated: 2026-05-15
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RecruitingNCT07114874
Start: 2025-07-11End: 2031-12-01Target: 600Updated: 2026-06-05
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization
RecruitingCTIS2025-521215-39-00
Start: 2025-12-08Target: 141Updated: 2025-11-10
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
RecruitingNCT07227818
Start: 2025-12-16End: 2029-07-01Target: 560Updated: 2026-06-05
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia
RecruitingCTIS2025-521216-19-00
Start: 2025-12-10Target: 151Updated: 2025-12-12